This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.
A large pragmatic randomized trial evaluated whether a bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine could reduce RSV-related hospitalizations among adults aged 60 years or...
In a nationwide Danish trial of more than 130,000 adults aged 60 years and older, a single dose of the bivalent RSV prefusion F protein vaccine reduced all-cause cardiorespiratory hospitalizations by nearly...
New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...
In this roundup, experts outline diverging pediatric COVID vaccine recommendations, midlife peaks in long COVID risk, new findings on abnormal uterine bleeding and cycle-related symptoms in long COVID, and...
New multicenter US data show that a single respiratory syncytial virus (RSV) vaccine dose protects against hospitalization in older adults, though effectiveness wanes over time and is lower in...
In a phase 1 trial, a single injection of an mRNA RSV vaccine boosted neutralizing antibody levels in seropositive children and was well tolerated, with no serious adverse events or study discontinuations...
